Clinical Trial Update: A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating disitamab vedotin plus tislelizumab and chemotherapy versus tislelizumab and chemotherapy in HER2-low advanced gastric …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Gastric Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING